Egetis Theraeutics Q2: Great US and European progress - Redeye

Egetis has rapidly transferred all but one German patient, supporting the launch and indicating positive acceptance of Emcitate at a favorable list price, supporting future European sales. The upcoming pre-NDA meeting with the FDA is significant in our view, setting the scene and the timetable ahead of the US launch.

Länk till analysen i sin helhet: https://www.redeye.se/research/1124342/egetis-theraeutics-q2-great-us-and-european-progress?utm_source=finwire&utm_medium=RSS